ALLEGAN — Perrigo Co. (Nasdaq: PRGO) announced that it has begun shipping Loratadine-D 12 hour extended release tablets, the store brand equivalent to Schering-Plough’s Claritin-D 12 hour extended release tablets.
Claritin-D 12 is indicated for the treatment of nasal allergy symptoms. Its estimated annual sales are approximately $111 million, according to data provided by Wolters, Kluwer.
“This launch is another milestone for our Consumer Healthcare segment, which is expected to launch many important new store brand products during this fiscal year,” said Perrigo chairman and CEO Joseph C. Papa. “We are excited to bring this important store brand medication to consumers for the first time and continue our focus on making quality healthcare more affordable.”
Perrigo develops, manufactures and distributes over-the-counter and generic prescription pharmaceuticals, infant formulas, nutritional products, and active pharmaceutical ingredients. The company is the world’s largest manufacturer of OTC pharmaceutical products and infant formulas, both for the store brand market. The company’s primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia.
More at www.perrigo.com.